OncoPharm

Next up in the Foundations of #OncoPharm series, gemcitabine.

We summarize the changes to ASCO's latest Antiemetic Guidelines update as well as their guidelines for chemotherapy-induced peripheral neuropathy (CIPN).

Then, we take a look at the PO decitabine approval and ponder the question, does low albumin decrease tolerability to some TKIs?

We're joined by Dr. Karen Fancher, oncology pharmacist, to talk about her breast cancer story from diagnosis to shared-decision making treatment plans with her oncologist to treatment toxicity.

While this is a topic best covered with case examples, we do our best to provide the basics in 20 minutes.

Experienced clinicians may not be aware of the How Long study briefly discussed in this episode: https://doi.org/10.1016/S2352-3026(17)30211-9

FDA ended June with 5 new approvals.

*selinexor for r/r DLBCL

*pembrolizumab for cutaneous squamous cell carcinoma

*pembrolizumab for MSI-h/dMMR met. colorectal cancer

*avelumab maintenance for met. bladder cancer

*SC trastuzumab/pertuzumab/hyaluronidase

A primer on primary endpoints used in oncology clinical trials. Tailored for those new to in-depth evaluations of oncology literature.

Topics on this week's Pod include:

-Lurbinectedin in SCLC

-Nivolumab is esophageal cancer

-Pembrolizumab for TMB-high cancers

-Gemtuzumab ozogamicin for pediatric AML

-Venetoclax + HMA for adult (unfit) AML

-Gardasil for prevention of SCCHN

-Perhaps the biggest non-oncopharm news of the year?

LD Vs Ld by John Bossaer

Recapping lots of updates from ASCO 2020.

Then (20:00) we chat with Shannon Hough, oncology pharmacy specialist, to talk about her ASCO abstract (https://meetinglibrary.asco.org/record/185996/abstract) on pharmacist interventions in managing CINV.

Another week, another two new approved indications in NSCLC. We cover Checkmate-9La (Nivo/Ipi + 2 cycles of chemo) and ALTA-1L (1st Line brigatinib in ALK-rearranged NSCLC).

Finally, we cover an interesting case report highlighting the need to determine CNS penetration of kinase inhibitors.

(Lots of ASCO talk *next* week!)